Puhakka Inka K, Sunela Kaisa L, Rönkä Aino L, Rajamäki Aino M, Arkko Ulla-Mari, Klaavuniemi Tuula M, Kuusisto Milla E L, Jäkälä Pekka A, Selander Tuomas A, Kuitunen Hanne K, Kantanen Anne-Mari, Kuittinen Outi M
Department of Neurology, Kuopio University Hospital, Puijonlaaksontie 2, 70210, Kuopio, Finland.
Department of Oncology, Tampere University Hospital, Tampere, Finland.
Ann Hematol. 2025 Jan;104(1):627-634. doi: 10.1007/s00277-024-06145-5. Epub 2024 Dec 19.
The optimal follow-up protocol for primary central nervous system lymphoma (PCNSL) is unclear. This is the first study to evaluate the benefit of structured follow-up imaging of PCNSL with respect to the timing of relapse.
A total of 198 PCNSL patients (57.1% males) diagnosed between 2003 and 2020 were included. The data were collected retrospectively from 8 hospitals in Finland. Relapse detection details included structured follow-up imaging (sMRI) studies, additional imaging (aMRI) studies based on patients' new symptoms, and all outpatient and emergency visits. Overall survival (OS) with respect to the relapse detection method, sMRI versus aMRI, was also evaluated.
Relapse was diagnosed in 71 patients (35.9%), 66.1% of whom experienced relapse during the first 2 years after diagnosis. During the first year, 48.3% (14/29) of the relapses were detected via sMRI, and 51.7% (15/29) via aMRI. During the second year, the percentages were 33.3% and 66.7%, respectively. More than 5 years after the diagnosis, all the relapses were detected via aMRI. To observe one relapse during the first year, 9.4 sMRI studies were needed. Overall survival after relapse (OS2) was 4.0 months for the patients whose first relapse was detected via sMRI and 3.0 months for those whose first relapse was detected via aMRI (P = 0.203).
We found that structured imaging was beneficial for relapse detection during the first year after PCNSL diagnosis. A minor trend towards better survival after relapse was observed for patients who experienced relapse according to structured imaging.
原发性中枢神经系统淋巴瘤(PCNSL)的最佳随访方案尚不清楚。这是第一项评估PCNSL结构化随访成像在复发时机方面益处的研究。
纳入了2003年至2020年间诊断的198例PCNSL患者(男性占57.1%)。数据从芬兰的8家医院回顾性收集。复发检测细节包括结构化随访成像(sMRI)研究、基于患者新症状的额外成像(aMRI)研究以及所有门诊和急诊就诊情况。还评估了复发检测方法(sMRI与aMRI)对总生存期(OS)的影响。
71例患者(35.9%)被诊断为复发,其中66.1%在诊断后的前2年内复发。在第一年,48.3%(14/29)的复发通过sMRI检测到,51.7%(15/29)通过aMRI检测到。在第二年,这两个百分比分别为33.3%和66.7%。诊断超过5年后,所有复发均通过aMRI检测到。在第一年观察到一次复发需要进行9.4次sMRI研究。首次复发通过sMRI检测到的患者复发后的总生存期(OS2)为4.0个月,首次复发通过aMRI检测到的患者为3.0个月(P = 0.203)。
我们发现结构化成像有助于在PCNSL诊断后的第一年检测复发。对于根据结构化成像复发的患者,观察到复发后生存情况有轻微改善的趋势。